Brincidofovir
INDICATIONS
FDA
FDA
- Treatment of human smallpox disease in adults and pediatric patients, including neonates
- Approved by the FDA in June 2021 for the treatment of smallpox through the FDA Animal Rule.
- It is NOT available for commercial sale, but Chimerix will work globally with public health agencies in the event the medication is needed for a smallpox outbreak.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Chimerix transferred exclusive rights for the development of brincidofovir for other indications (e.g., adenovirus) to SymBio Pharmaceuticals Ltd in 2019.
- Any requests for brincidofovir other than for smallpox should be submitted to SymBio.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 23, 2022
Citation
Dzintars, Kathryn. "Brincidofovir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540772/all/Brincidofovir.
Dzintars K. Brincidofovir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540772/all/Brincidofovir. Accessed December 1, 2024.
Dzintars, K. (2022). Brincidofovir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540772/all/Brincidofovir
Dzintars K. Brincidofovir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 December 01]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540772/all/Brincidofovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Brincidofovir
ID - 540772
A1 - Dzintars,Kathryn, Pharm.D., BCPS
Y1 - 2022/06/23/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540772/all/Brincidofovir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -